To also mimic therapeutic approaches in CLL patients that already have high levels of CLL in the peripheral blood at the time of treatment initiation, we also tested the efficacy of SHIP1 inhibition in a highly aggressive mCLL where the disease had progressed to ~50% CD19+ CD5+ cells in the peripheral blood at the time of treatment initiation (Fig. 3d). The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.